Diabetes is a chronic disease that affects a large part of the United States population. The majority of patients with diabetes will experience gastrointestinal symptoms. One of the most troublesome gastrointestinal symptoms that diabetes can cause is diarrhea, otherwise known as "Diabetic Diarrhea." This occurs because diabetes does damage to nerves that control the gut and prevent it from functioning normally. Currently, there are only several medications used to treat the symptoms of Diabetic Diarrhea, but many of these medications have serious side effects or do not work well.
We are investigating the drug eluxadoline for the treatment of Diabetic Diarrhea. Eluxadoline is a gut-specific medication that is FDA approved to treat diarrhea related to irritable bowel syndrome (IBS-D). Our hypothesis is eluxadoline will safely and successfully reduce diarrhea symptoms (number of stools and less liquid stools) and improve the quality of life in patients with Diabetic Diarrhea when compared with placebo. Each patient with Diabetic Diarrhea who participates will take both eluxadoline and a placebo drug at separate times over a period of several months as part of a crossover study design. While on each medication, eluxadoline or placebo, the participants will keep a diary of symptoms and will be followed by the medical team through a combination of office visits and questionnaires. There will be five planned office visits and intermittent phone calls (questionnaires, surveys) over the 140-day study period. Participants will not be permitted to use any other anti-diarrhea medication during the study period and will continue on medication for management of their diabetes.

开始日期2022-07-01

申办/合作机构

Temple University Graduate School

[+1]

NCT04880876 / Enrolling by invitation临床3期

A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.

开始日期2021-08-13

申办/合作机构

AbbVie, Inc.

NCT03489265 / Withdrawn临床2期IIT

Treatment of Diarrhea-Associated Fecal Incontinence With Eluxadoline

Accidental bowel leakage (fecal incontinence) increases in people who have diarrhea and sensations of urgency to have a bowel movement. Drugs such as loperamide (Imodium) that reduce diarrhea improve accidental bowel leakage, but loperamide has disadvantages: it is difficult to find a dose that does not cause constipation, and it does not reduce urge sensations. Eluxadoline is a new drug that is effective for reducing diarrhea, abdominal pain, and urgency in patients with irritable bowel syndrome, and it may be less likely than loperamide to cause severe constipation. Therefore, eluxadoline may help patients manage accidental bowel leakage caused by diarrhea. The chemical name for Viberzi® is eluxadoline.
The primary aims of this study are to find out if eluxadoline at a dose of 100 mg orally twice a day will reduce the average number of days the patient has accidental bowel leakage, and to see if the rate of accidental bowel leakage increases when the patient stops taking eluxadoline. Additional goals are to find out if eluxadoline decreases diarrhea and urge sensations.
This is a small (pilot) study to show whether eluxadoline is an effective way of treating accidental bowel leakage. If the study shows this, a larger study will be needed. There are three phases to this 12-week study: (1) A two-week run-in period to see if the patient meets the inclusion criteria. (2) Two months for treatment including one month on eluxadoline and one on placebo (sugar pills) twice a day. (3) A two-week follow-up to see what happens when you stop taking eluxadoline.
To participate in the study, patients should be aged 18 or older. Patients with inflammatory bowel disease, anal fissures, or congenital malformations will be excluded.
The primary outcome is the average number of days per week with any solid or liquid bowel accidents. Additional information includes: (1) Number of days per week the patient takes loperamide, (2) days per week with loose or watery stools, (3) days per week with moderate to strong urge sensations, and (4) questionnaires to measure the severity of accidental bowel leakage, quality of life, anxiety, and depression. There will be up to 38 patients in the study.

开始日期2019-04-01

申办/合作机构

The University of North Carolina at Chapel Hill

[+1]

100 项与艾沙度林相关的临床结果

登录后查看更多信息

100 项与艾沙度林相关的转化医学

登录后查看更多信息

100 项与艾沙度林相关的专利（医药）

登录后查看更多信息

157

项与艾沙度林相关的文献（医药）

2023-10-01·Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.

Article

作者: Rosón, Benigno ; Ares-Gómez, Sonia ; Salas, Antonio ; González-Pérez, Juan-Manuel ; Martinón-Torres, Federico ; Mirás-Carballal, Susana ; Pardo-Seco, Jacobo ; Mallah, Narmeen ; López-Pérez, Luis-Ricardo ; Durán-Parrondo, Carmen ; Gómez-Carballa, Alberto ; Nartallo-Penas, Victoria ; Rodríguez-Tenreiro-Sánchez, Carmen ; Rivero-Calle, Irene ; Otero-Barrós, María-Teresa

BACKGROUND:

Studies on vaccine effectiveness (VE) against COVID-19 in the pediatric population are outgoing. We aimed to quantify VE against SARS-CoV-2 in two pediatric age groups, 5-11 and 12-17-year-old, while considering vaccine type, SARS-CoV-2 variant, and duration of protection.

METHODS:

A population-based test-negative control study was undertaken in Galicia, Spain. Children 5-11-year-old received the Comirnaty® (Pfizer, US) vaccine, while those aged 12-17-year-old received the Comirnaty® (Pfizer, US) or SpikeVax® (ModernaTX, Inc) vaccine. Participants were categorized into unvaccinated (0 doses or one dose with <14 days since vaccination), partially vaccinated (only one dose with ≥14 days, or two doses with <14 days after the second dose administration), and fully vaccinated (two doses with ≥14 days after the second injection). Adjusted odds ratios (OR) and their 95% confidence intervals (CI) were estimated using multiple logistic regression models. VE was calculated as (1-OR) * 100. Stratified and sensitivity analyses were performed.

RESULTS:

In the fully vaccinated 5-11-year-old children, VE against the Omicron variant was 44.1% (95% CI: 38.2%-49.4%). In the fully vaccinated 12-17-year-old individuals, VE was 83.4% (95% CI: 81.2%-85.3%) against Delta and 74.8% (95% CI: 58.5%-84.9%) against Omicron. Comirnaty® and SpikeVax® vaccines showed a similar magnitude of VE against Delta [Comirnaty® VE: 81.9% (95% CI: 79.3%-84.1%) and SpikeVax® VE: 85.3% (95% CI: 81.9%-88.1%)]. Comirnaty® (Pfizer, US; VE: 79.7%; 95% CI: 50.7%-92.4%) showed a slightly higher magnitude of protection against Omicron than SpikeVax® (ModernaTX, Inc), yet with an overlapping CI (VE: 74.3%; 95% CI: 56.6%-84.9%). VE was maintained in all age subgroups in both pediatric populations, but it declined over time.

CONCLUSIONS:

In Galicia, mRNA VE was moderate against SARS-CoV-2 infections in the 5-11-year-old populations, but high in older children. VE declined over time, suggesting a potential need for booster dose schedules.

2023-07-01·Computers in biology and medicine

Identification of core therapeutic targets for Monkeypox virus and repurposing potential of drugs against them: An in silico approach.

Article

作者: Mahanandia, Nimai Charan ; Swain, Ranjit Prasad ; Sahu, Anshuman ; Gaur, Mahendra ; Subudhi, Bharat Bhusan ; Subudhi, Enketeswara

Monkeypox virus (mpox virus) outbreak has rapidly spread to 82 non-endemic countries. Although it primarily causes skin lesions, secondary complications and high mortality (1-10%) in vulnerable populations have made it an emerging threat. Since there is no specific vaccine/antiviral, it is desirable to repurpose existing drugs against mpox virus. With little knowledge about the lifecycle of mpox virus, identifying potential inhibitors is a challenge. Nevertheless, the available genomes of mpox virus in public databases represent a goldmine of untapped possibilities to identify druggable targets for the structure-based identification of inhibitors. Leveraging this resource, we combined genomics and subtractive proteomics to identify highly druggable core proteins of mpox virus. This was followed by virtual screening to identify inhibitors with affinities for multiple targets. 125 publicly available genomes of mpox virus were mined to identify 69 highly conserved proteins. These proteins were then curated manually. These curated proteins were funnelled through a subtractive proteomics pipeline to identify 4 highly druggable, non-host homologous targets namely; A20R, I7L, Top1B and VETFS. High-throughput virtual screening of 5893 highly curated approved/investigational drugs led to the identification of common as well as unique potential inhibitors with high binding affinities. The common inhibitors, i.e., batefenterol, burixafor and eluxadoline were further validated by molecular dynamics simulation to identify their best potential binding modes. The affinity of these inhibitors suggests their repurposing potential. This work can encourage further experimental validation for possible therapeutic management of mpox.

2023-05-10·Pharmaceutics

Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box-Behnken Design, and Anti-Diarrheal Activity.

Article

作者: Ahmed, Mohammed Muqtader ; Anwer, Md Khalid ; Soliman, Gamal A ; Aljuffali, Ibrahim A ; Aldawsari, Mohammed F ; Iqbal, Muzaffar

Eluxadoline (ELD), a recently approved drug, exhibits potential therapeutic effects in the management and treatment of IBS-D. However, its applications have been limited due to poor aqueous solubility, leading to a low dissolution rate and oral bioavailability. The current study's goals are to prepare ELD-loaded eudragit (EG) nanoparticles (ENPs) and to investigate the anti-diarrheal activity on rats. The prepared ELD-loaded EG-NPs (ENP1-ENP14) were optimized with the help of Box-Behnken Design Expert software. The developed formulation (ENP2) was optimized based on the particle size (286 ± 3.67 nm), PDI (0.263 ± 0.01), and zeta potential (31.8 ± 3.18 mV). The optimized formulation (ENP2) exhibited a sustained release behavior with maximum drug release and followed the Higuchi model. The chronic restraint stress (CRS) was successfully used to develop the IBS-D rat model, which led to increased defecation frequency. The in vivo studies revealed a significant reduction in defecation frequency and disease activity index by ENP2 compared with pure ELD. Thus, the results demonstrated that the developed eudragit-based polymeric nanoparticles can act as a potential approach for the effective delivery of eluxadoline through oral administration for irritable bowel syndrome diarrhea treatment.

项与艾沙度林相关的新闻（医药）

2024-06-04

·PRNewswire

Analysis Group Researchers Suggest a Novel Approach to Measuring Real-World Treatment Effectiveness for Irritable Bowel Syndrome with Diarrhea

BOSTON, June 4, 2024 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored a study detailing how treatment-free intervals (TFIs) can be an effective surrogate in retrospective data analyses for understanding therapy effectiveness for conditions that present multifaceted symptoms across widely divergent patient populations, such as irritable bowel syndrome with diarrhea (IBS-D). The study, published in the journal Advances in Therapy, is the first to use TFIs to assess real-world IBS-D therapy response, using two of the most commonly prescribed treatments in the US: rifaximin and eluxadoline. While the Food and Drug Administration (FDA) recommends using a five-item opinion-based questionnaire to measure patient-reported outcomes (PROs) that capture clinically important signs and symptoms to define treatment effects in clinical trials, it is challenging to apply this method to evaluate real-world outcomes in retrospective studies. The difficulty lies in the complex presentation of IBS-D, a common, chronic, relapsing, and potentially severe disorder of gut–brain interaction characterized by troublesome symptoms such as abdominal pain, diarrhea, fecal urgency, and bloating. To overcome these challenges, study investigators analyzed US commercial claims data for 9,255 IBS-D patients receiving one of the two treatments over the course of one year. The researchers focused on patients' TFI patterns – the length of time a patient remains off treatment after a course of therapy. Patient characteristics included age, sex, health plan type, region, and provider specialty, as of the index date. During baseline, medically relevant comorbidities (both gastrointestinal- and mental health–related), procedures (e.g., anesthesia, surgery, radiation services), and treatments were reported. Investigators specifically examined the duration of the index treatment, the number of prescription fills, and all-cause health care costs among adult patients with IBS-D treated with rifaximin or eluxadoline. The researchers concluded that TFIs may be a meaningful proxy for measuring treatment effectiveness in IBS-D. Using this method, they also found that patients treated with rifaximin had longer TFIs and lower health care costs than patients treated with eluxadoline. "The challenges of studying IBS-D are similar in many ways to those faced with oncology, where important treatment goals include medication-free periods associated with symptom control, especially when there is a treatment-related toxicity or financial burden associated with treatment changes or combination therapy," said study investigator Annie Guérin, a Managing Principal with Analysis Group. "Our approach to using TFIs was based on the proven strategies used in oncology, where patients value treatment-free periods because they are associated with improved health-related quality of life." The study, "Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea," was published in April in Advances in Therapy. In addition to Ms. Guérin, investigators included Vice President Patrick S. Gagnon, Associate Rebecca Bungay, and Senior Research Professional Remi Bellefleur of Analysis Group; Brian E. Lacy of Mayo Clinic; Zeev Heimanson of Salix Pharmaceuticals; Brock Bumpass, Danellys Borroto, and Ankur A. Dashputre of Bausch Health; and George Joseph of BioNTech US. Funding was provided by Bausch Health. To learn more about Analysis Group's HEOR capabilities, visit About Analysis Group's HEOR, Epidemiology & Market Access Practice Founded in 1981, Analysis Group is one of the largest international economics consulting firms, with more than 1,200 professionals across 14 offices. Analysis Group's health care experts apply analytical expertise to health economics and outcomes research (HEOR), clinical research, market access and commercial strategy, and health care policy engagements, as well as drug safety-related engagements in epidemiology. Analysis Group's internal experts, together with our network of affiliated experts from academia, industry, and government, provide our clients with exceptional breadth and depth of expertise and end-to-end consulting services globally. Contact: Analysis Group Eric Seymour, +1 978 273 6049 [email protected] SOURCE Analysis Group

放射疗法临床结果临床研究

2024-05-31

·佰傲谷BioValley

甩锅侠Biotech的穷途末路

近日，Virios Therapeutics公司宣布配售850万股普通股，发行价为每股0.20美元，此次配售拟筹资净额170万美元，该笔资金将用于其抗病毒组合疗法IMC-2（valacyclovir +celecoxib)的Ⅱb期临床开展以及一般公司用途。截至统计当日，Virios的股价0.20美元。一次融资Virios Therapeutics专注于新型抗病毒疗法开发，治疗与病毒感染引起的免疫相关疾病。Virios在2020年12月在纳斯达克上市，发行价9-11美元/股，筹集3000万美元资金，这也是公司至今公开披露唯一募集到的资金。上市前，公司仅有一条管线IMC-1，一种amciclovir+celecoxib的抗病毒组合疗法，旨在协同抑制单纯疱疹病毒HSV-1的激活和复制，最终降低HSV-1介导的疾病症状。HSV-1是疱疹病毒科中感染人类的病毒，在人群中普遍存在且通过接触传染。由HSV-1激活的过度免疫应答被认为是如纤维肌痛（FM）、肠易激疾病（IBS）、慢性疲劳综合征（CFS）等慢性疾病的发病原因。基于此，Virios开发了FM、IBS、CFS三种临床适应症。2016年，IMC-1获得了FDA授予快速通道资格。甩锅行为2021年7月，Virios启动了IMC-1的Ⅱ期临床试验。在Ⅱa期临床试验中，与安慰剂相比，IMC-1使得FM患者的疼痛明显减轻。而在2022年，IMC-1遭遇了重大失败。2022年9月，Viirios公布了IMC-1治疗FM的II期FORTRESS顶线数据，在所有患者中，相较于安慰剂，Viirios的组患者的疼痛严重程度未得到改善。不过，Virios并不承认失败结果，而是将失败原因甩锅给了Delta毒株和入组患者。在事后分析中，Virios发现，其中214位患者疼痛症状改善程度上优于安慰剂组，而这批患者是临床后半阶段入组的患者。考虑到入组时间上的差异，Virios终于找到了临床失败的原因：在该临床的后半程，新冠疫苗接种率提高，Omicron取代Delta成为了新冠流行毒株。由此，公司认为是不同的COVID-19毒株与HSV-1激活之间的相互作用造成了不同时期入组患者疗效上的差异。此外，Viirios进一步分析发现，其中女性患者的疼痛症状改善更为显著，公司声称如果入组患者只包括这些女性，该试验结果将是积极的。对于这种无稽之谈的解释，市场迅速给出了抗议态度，Virios股价连续两天暴跌75%。虽然IMC-1仍在管线中，资金用途中尚未提及IMC-1，该管线可能已经被Viirios放弃。两面说辞除了临床数据之外，公司对自己的财务处境似乎也有些自欺之意。据公司2024一季度业绩报告会披露，截至2024年3月31日，公司现金总额为240万美元，2024Q1公司净亏损-130万美元。这时，公司认为将有足够的资金支撑公司运营2024年第四季度。然而在SEC备案的季度报中，公司认为需要在未来五个月内筹集到资金，不然难以维持未来的经营。前后对其所面临的运营处境是截然不同的态度。Virios在股市早已没有流动性，即便如此低的发行价，对于这家成立以来就不为投资者待见的甩锅Biotech公司，想要募集到资金仍然不甚乐观。参考出处：https://www.fiercebiotech.com/special-reports/fierce-biotechs-rotten-tomatoes-2022https://www.biospace.com/article/releases/virios-therapeutics-announces-pricing-of-1-7-million-public-offering-of-common-stock-to-commence-preparations-for-planned-imc-2-long-covid-phase-2b-study/https://www.nasdaq.com/press-release/virios-therapeutics-announces-first-quarter-2024-financial-results-and-provideshttps://www.virios.com/imc-1https://ir.virios.com/sec-filings/all-sec-filings/content/0001558370-24-007713/0001558370-24-007713.pdf本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处········

临床2期疫苗快速通道

2023-06-07

·drugs

What Is Irritable Bowel Syndrome?

WEDNESDAY, June 7, 2023 -- People who suffer from irritable bowel syndrome (IBS) know it is a highly unpleasant chronic condition that can trigger abdominal pain, diarrhea and constipation. Here, experts will unravel the mysteries of IBS, exploring its causes, symptoms and treatments. And of course, don't forget about the role of diet. Experts will break down the best foods to eat and those to avoid for a happy gut. What is irritable bowel syndrome? According to the Mayo Clinic , irritable bowel syndrome is a common disorder targeting the gastrointestinal tract, encompassing the stomach and intestines. This chronic condition manifests through a range of distressing symptoms, including cramping, abdominal pain, bloating, excessive gas and the frustrating duo of diarrhea and constipation, which may occur individually or even simultaneously. Dealing with IBS requires a long-term management approach to address its persistent impact on daily life effectively. What causes IBS? The exact causes of irritable bowel syndrome remain uncertain, according to the National Institute of Diabetes and Digestive and Kidney Issues (NIDDK). However, experts believe that a combination of factors contributes to its development. IBS is considered a functional gastrointestinal (GI) disorder involving the intricate interaction between the brain and the gut. Here are some potential causes and factors that may play a role in IBS: Problems with brain-gut interaction. Brain and gut communication can impact the body's functioning, triggering IBS symptoms. This can include abnormal food movement through the digestive tract, resulting in changes in bowel movements, and experiencing pain even with average amounts of gas or stool in the gut. Stressful or difficult early-life events. Traumatic experiences during childhood, such as physical or sexual abuse, have been associated with an increased risk of developing IBS. Mental disorders. Conditions like depression, anxiety and somatic symptom disorder are more common among individuals with IBS and may contribute to its onset. Bacterial infections. Infections of the digestive tract caused by certain bacteria have been linked to developing IBS. Small intestinal bacterial overgrowth. In terms of increased numbers or changes in the bacterial type, an overgrowth of bacteria in the small intestine has been associated with IBS. Food intolerances or sensitivities. Some individuals with IBS may experience digestive symptoms triggered by specific foods, indicating intolerances or sensitivities to certain dietary components. The causes of IBS can vary among individuals, highlighting this condition's complexity. IBS symptoms In a recent video with Dr. Jennifer Webster , a pediatric gastroenterologist with Children’s Hospital of Philadelphia, she indicates that “the tricky thing about IBS is that there is no specific test that we can use to say 100% you have this . We do lots of testing to rule out other diseases. Similar to migraines, there isn’t a test, but we know that the pain is real and the symptoms are real.” While some studies suggest potential differences in the prevalence and severity of IBS symptoms between men and women, it is worth noting that the core symptoms are relatively similar. Here are some typical symptoms of IBS in men and women, according to Johns Hopkins Medicine : Abdominal pain or cramping. This is one of the hallmark symptoms of IBS. The pain is often described as a lower abdominal discomfort or cramping sensation that may vary in intensity. Bloating and distention. Many individuals with IBS experience bloating, a feeling of increased pressure or fullness in the abdomen. This can be accompanied by visible abdominal distention or swelling. Altered bowel habits. IBS can lead to changes in bowel movements. These changes can include diarrhea, characterized by loose or watery stools, and constipation, characterized by infrequent or difficult bowel movements. Some individuals may alternate between episodes of diarrhea and constipation. Excessive gas. Many people with IBS may notice increased gas production, leading to bloating, belching or flatulence. Urgency or an incomplete bowel movement. Some individuals with IBS may experience a sense of urgency to have a bowel movement or feel as though they haven't fully emptied their bowels after a bowel movement. Mucus in the stool. In some cases, people with IBS may notice the presence of mucus in their stool. Can a specific diet for IBS help with symptoms? When managing symptoms of IBS, changing your diet can play a significant role. Here are some common dietary recommendations for individuals with IBS: The NIDDK suggests the following foods to eat with irritable bowel syndrome : Increase fiber intake. Focus on incorporating sources of soluble fiber, such as oats, bananas, carrots and psyllium husk, into your diet. Avoid gluten. Avoiding gluten-containing grains like wheat, barley and rye may be beneficial for individuals with gluten sensitivity or celiac disease. Opt for gluten-free alternatives like quinoa, rice and gluten-free oats. Follow a low-FODMAP diet. Following a special diet known as the low- FODMAP diet may provide relief for some individuals with IBS. This diet for IBS involves temporarily restricting certain high-FODMAP foods, such as onions, garlic, wheat and fruits such as apples, cherries, nectarines, pears and watermelon, or juice containing any of these fruits, then gradually reintroducing them to identify specific triggers. IBS treatments The treatment of IBS aims to alleviate symptoms, allowing individuals to live as symptom-free as possible. Depending on your symptoms, your health care provider may recommend different approaches on how to treat your IBS, including medication and IBS self-care strategies. Here are some commonly prescribed irritable bowel syndrome medications as indicated by the Mayo Clinic: Alosetron (Lotronex). This medication is designed to relax the colon and slow down the movement of waste through the lower bowel. It is primarily prescribed for severe cases of IBS in women and is not approved for use in men. Eluxadoline (Viberzi). Eluxadoline is a medication that aids in reducing diarrhea by decreasing fluid secretion and muscle contractions in the intestine while simultaneously enhancing muscle tone in the rectum. Rifaximin (Xifaxan). This antibiotic decreases bacterial overgrowth in the gut and relieves diarrhea symptoms. Lubiprostone (Amitiza). Lubiprostone increases fluid secretion in the small intestine, aiding in the passage of stool. It is approved for women with IBS with constipation. Linaclotide (Linzess). Linaclotide also increases fluid secretion in the small intestine to facilitate bowel movements. Living with IBS Living with IBS can be challenging, but there are ways to manage its symptoms and improve your quality of life. Working closely with health care professionals allows you to explore dietary modifications, medication options and self-care strategies tailored to your needs. Posted June 2023

上市批准

100 项与艾沙度林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10403	艾沙度林	A07DA06	DB09272

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
腹泻型肠易激综合征	欧盟	Allergan Pharmaceuticals International Ltd.	2016-09-19
腹泻型肠易激综合征	冰岛	Allergan Pharmaceuticals International Ltd.	2016-09-19
腹泻型肠易激综合征	列支敦士登	Allergan Pharmaceuticals International Ltd.	2016-09-19
腹泻型肠易激综合征	挪威	Allergan Pharmaceuticals International Ltd.	2016-09-19
肠易激综合征	美国	AbbVie, Inc.	2015-05-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腹泻	临床2期	美国	AbbVie, Inc.	2017-11-15
腹泻	临床2期	保加利亚	AbbVie, Inc.	2017-11-15
腹泻	临床2期	加拿大	AbbVie, Inc.	2017-11-15
腹泻	临床2期	匈牙利	AbbVie, Inc.	2017-11-15
腹泻	临床2期	荷兰	AbbVie, Inc.	2017-11-15
腹泻	临床2期	波兰	AbbVie, Inc.	2017-11-15
腹泻	临床2期	英国	AbbVie, Inc.	2017-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03441581 (3030-401-002, CTgov)	临床4期	胆汁酸吸收不良（BAM） \| 腹泻型肠易激综合征	24	Eluxadoline (Eluxadoline 100 mg With BAM)	齋衊獵鏇獵齋構願積鬱(壓廠窪鏇築網廠繭鏇餘) = 蓋選顧繭壓餘網夢糧餘醖範齋簾繭夢簾齋膚積 (憲齋襯鏇衊醖構襯窪鏇, 餘窪鏇窪遞鬱築鬱淵廠 ~ 選網簾壓簾範窪醖積積) 更多	-	2021-05-19
				Eluxadoline (Eluxadoline 100 mg Without BAM)	齋衊獵鏇獵齋構願積鬱(壓廠窪鏇築網廠繭鏇餘) = 鬱鹹獵積鹽構齋醖構艱醖範齋簾繭夢簾齋膚積 (憲齋襯鏇衊醖構襯窪鏇, 蓋願醖襯壓簾糧鏇製遞 ~ 艱衊選膚鏇襯齋壓獵簾) 更多
NCT01130272 (CTgov)	临床2期	腹泻 \| 肠易激综合征	807	Eluxadoline (Eluxadoline 5 mg)	簾鏇蓋艱簾遞鏇網鏇獵(壓餘範壓網衊鹽憲淵鹹) = 選廠鹹積糧膚窪積齋廠顧獵鹹繭齋艱憲窪遞窪 (築窪繭選積鑰遞壓衊艱, 壓願積衊願鏇選構繭憲 ~ 壓窪艱窪蓋積廠積窪糧) 更多	-	2019-10-22
				Eluxadoline (Eluxadoline 25 mg)	簾鏇蓋艱簾遞鏇網鏇獵(壓餘範壓網衊鹽憲淵鹹) = 願遞醖鑰壓遞積鬱構壓顧獵鹹繭齋艱憲窪遞窪 (築窪繭選積鑰遞壓衊艱, 顧鹽鑰觸鬱艱憲網獵廠 ~ 衊築網鬱範糧網鹹醖鹽) 更多
NCT02959983 (RELIEF, Pubmed \| Am J Gastroenterol) 人工标引	临床4期	腹泻 \| 肠易激综合征	346	Eluxadoline	簾糧襯夢繭觸窪夢範襯(憲醖憲顧範顧糧艱糧憲) = 蓋艱鏇艱衊積繭願窪壓鏇遞壓築鹽蓋選衊淵鏇 (醖範餘鹽糧範願蓋憲窪 ) 更多	积极	2019-09-01
				Placebo	簾糧襯夢繭觸窪夢範襯(憲醖憲顧範顧糧艱糧憲) = 艱鏇廠廠憲築鹹醖遞網鏇遞壓築鹽蓋選衊淵鏇 (醖範餘鹽糧範願蓋憲窪 ) 更多
NCT02959983 (CTgov)	临床4期	腹泻型肠易激综合征 \| 腹泻	346	Eluxadoline (Eluxadoline)	製鬱鬱鹽獵壓蓋壓範艱(壓憲窪憲顧鏇襯餘齋鹽) = 遞膚築範製壓鹹獵壓壓遞餘鏇範淵淵製淵齋簾 (積構鏇鏇膚範鏇餘廠積, 願鑰餘蓋窪窪壓製構鹹 ~ 範獵積遞衊鑰構遞窪醖) 更多	-	2019-02-15
				Placebo (Placebo)	製鬱鬱鹽獵壓蓋壓範艱(壓憲窪憲顧鏇襯餘齋鹽) = 選鬱範艱鏇範網壓築廠遞餘鏇範淵淵製淵齋簾 (積構鏇鏇膚範鏇餘廠積, 鏇範餘網繭淵衊積鬱遞 ~ 襯餘繭築齋鏇衊鹹繭獵) 更多
NCT01553591 (CTgov)	临床3期	腹泻型肠易激综合征	1,282	Eluxadoline (Eluxadoline 75 mg)	網簾齋鏇襯製衊製淵窪(繭餘壓鹹鹽糧餘範網顧) = 範艱廠顧選獵窪積憲膚鑰壓獵顧膚醖範艱網夢 (憲繭積齋觸餘簾淵鬱觸, 積衊積蓋繭鬱齋獵築夢 ~ 壓鬱艱襯網網選鑰鬱鏇) 更多	-	2018-09-04
				Eluxadoline (Eluxadoline 100 mg)	網簾齋鏇襯製衊製淵窪(繭餘壓鹹鹽糧餘範網顧) = 餘繭鑰蓋積獵鹹餘獵夢鑰壓獵顧膚醖範艱網夢 (憲繭積齋觸餘簾淵鬱觸, 憲鹽積齋蓋廠艱鹹鬱襯 ~ 壓醖顧構鹽簾夢壓築選) 更多
NCT01553747 (CTgov)	临床3期	腹泻型肠易激综合征	1,146	Eluxadoline (Eluxadoline 75 mg)	願鏇艱獵範遞鑰選壓餘(齋廠蓋膚積壓餘觸廠淵) = 製憲願衊製憲鏇衊醖獵製衊壓壓獵壓築觸衊獵 (簾鏇衊觸蓋齋願構觸糧, 壓顧淵築觸齋簾蓋觸夢 ~ 鬱築膚鹽鬱艱鏇襯構構) 更多	-	2018-07-30
				Eluxadoline (Eluxadoline 100 mg)	願鏇艱獵範遞鑰選壓餘(齋廠蓋膚積壓餘觸廠淵) = 壓遞鹽鹽齋襯獵艱壓構製衊壓壓獵壓築觸衊獵 (簾鏇衊觸蓋齋願構觸糧, 糧範憲鑰觸遞鹹壓淵壓 ~ 鹽積廠積襯餘膚鹽鏇製) 更多
IBS-3001 and IBS-3002 (Pubmed \| Br Dent J)	临床3期	腹泻型肠易激综合征	2,427	Eluxadoline 75 mg	蓋願糧網繭糧遞鑰願鏇(遞積艱鏇範鹹鑰顧襯壓) = 製顧蓋壓獵艱鬱憲夢膚糧夢衊淵膚繭範窪鹹壓 (餘膚膚艱蓋齋繭廠齋鹽 ) 更多	-	2016-01-21
				Eluxadoline 100 mg	蓋願糧網繭糧遞鑰願鏇(遞積艱鏇範鹹鑰顧襯壓) = 鏇築窪選齋憲鑰廠壓蓋糧夢衊淵膚繭範窪鹹壓 (餘膚膚艱蓋齋繭廠齋鹽 ) 更多
NCT01130272 (Pubmed \| J Laparoendosc Adv Surg Tech A) 人工标引	临床2期	腹泻 \| 肠易激综合征	807	Eluxadoline	醖壓淵糧醖網網簾積網(鹹壓鹽繭壓鹽鹽觸鹽窪) = 齋網願鹽鬱鏇憲艱願觸鹹鑰壓願齋憲蓋簾淵膚 (願願蓋簾鑰夢鑰選憲鹹 ) 更多	积极	2013-08-01
				Placebo	醖壓淵糧醖網網簾積網(鹹壓鹽繭壓鹽鹽觸鹽窪) = 壓鬱憲網願齋衊蓋窪壓鹹鑰壓願齋憲蓋簾淵膚 (願願蓋簾鑰夢鑰選憲鹹 ) 更多